East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Upadacitinib
Rinvoq
Routinely available
SMC (SMC2532)
29/03/2023

Indication

For the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

For the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).

Therapeutic Area

Musculoskeletal and joint diseases

Status Description

Routinely available in line with national guidance

Formulation

15mg prolonged-release tablets

Comments

March 2023 - Routinely available in line with national guidance. Included on the ERF for Specialist Use only.

Link to Advice

SMC2532

Advice Published

13/02/2023

SMC Submission Type

Abbreviated

SMC Status

Accepted